« Back to Farmacia Journal 6/2017
DOUBLE THERAPY WITH PEGYLATED INTERFERON AND RIBAVIRIN FOR CHRONIC HEPATITIS C. A PHARMACOGENETIC GUIDE FOR PREDICTING ADVERSE EVENTS
ADINA MARIA KAMAL 1#, PAUL MITRUȚ 1#, ANCA OANA DOCEA 2#, SIMONA ȘERBAN ȘOȘOI 3#, CONSTANTIN KAMAL KAMAL 4#*, RADU MITRUȚ 5#, DRAGOȘ MĂRGĂRITESCU 6#, DANIELA CĂLINA 7#, CRISTIAN BANCIU 8#, OANA SORINA TICA 9#, ANDREI ADRIAN TICA 9#, DRAGOȘ O. ALEXANDRU 10#
1.Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, Romania
2.Department of Toxicology, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Romania
3.Department of Medical Genetics, University of Medicine and Pharmacy of Craiova, Romania
4.Department of Family Medicine, University of Medicine and Pharmacy of Craiova, Romania
5.University of Medicine and Pharmacy of Craiova, Romania
6.Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania
7.Department of Clinical Pharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Romania
8.Department of Internal Medicine, Faculty of Medicine, “Victor Babeș” University of Medicine and Pharmacy Timișoara, Romania
9.Department of Pharmacology, University of Medicine and Pharmacy of Craiova, Romania
10.Department of Medical Informatics, University of Medicine and Pharmacy of Craiova, Romania